NEW YORK, March 20, 2017 /PRNewswire/ -- Oppenheimer
& Co. Inc. ("Oppenheimer") a unit of Oppenheimer Holdings
(NYSE: OPY), announced the hiring of a new Life Sciences team to
join the firm's Healthcare Investment Banking Group. The team is
led by Michael A. Margolis, R.Ph.,
who will serve as Managing Director and Co-Head of Healthcare
Investment Banking along with Marc
Cabrera who leads the Healthcare Services and Digital Health
team.
Margolis brings to Oppenheimer over two decades of Investment
Banking experience in the Life Sciences sectors. Most recently,
Margolis served as the Head of Healthcare Investment Banking at
ROTH Capital Partners. He previously held a number of key positions
in the financial services and pharmaceutical industries, including
roles at Novartis Pharmaceuticals and Eli Lilly. In addition, he is
a registered pharmacist from Rutgers
University, College of Pharmacy.
Michael is joined by Warren Dunnavant
II, Managing Director of Healthcare Investment Banking.
Dunnavant also joins the firm from ROTH Capital Partners, where he
previously served as a Managing Director in Healthcare Investment
Banking. Previously, Warren held positions in Investment Banking
and Equity Research at Stifel Nicolaus & Co., Legg Mason and Lehman Brothers.
Collectively, Margolis and Dunnavant have executed more than 300
financing and strategic advisory transactions and raised in excess
of $12.5 billion during their tenure
at ROTH Capital Partners.
"As big pharma continues to deal with patent expirations, we see
strong tailwinds for the life sciences sector," said Rob Lowenthal, Head of Investment Banking at
Oppenheimer. "In 2015, biotechnologies represented seven of the top
10 drugs and over the next five years, global biotech revenue is
estimated to grow to over $300
billion. This fundamental growth trend will drive new
company and capital formation across life sciences. With the
addition of Michael and his team, Oppenheimer's healthcare
investment banking effort is well- positioned for continued
success."
"I am excited to join the Oppenheimer platform and continue to
strengthen our presence in the healthcare sector," said
Michael A. Margolis, Managing
Director, Co-Head of Healthcare for Oppenheimer's Investment
Banking team. "We look forward to providing established and
emerging growth life sciences companies with industry leading
advice. With the full support of the Oppenheimer franchise, our
team will be well-positioned to help clients achieve their
financing and strategic objectives."
The announcement comes right as Oppenheimer kicks off its
27th Annual Healthcare Conference in New York City on March
21. The two-day conference brings together more than 100
leading public and private companies across major sectors of the
healthcare industry with investors. The event offers one-on-one
settings and small group meetings for investors to meet with
company management teams.
Oppenheimer & Co. Inc.
Oppenheimer & Co. Inc.
(Oppenheimer), a principal subsidiary of Oppenheimer Holdings Inc.
(OPY on the New York Stock Exchange), and its affiliates provide a
full range of wealth management, securities brokerage and
investment banking services to high-net-worth individuals,
families, corporate executives, local governments, businesses and
institutions.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oppenheimer--co-inc-expands-its-healthcare-investment-banking-by-adding-a-leading-life-sciences-team-300426088.html
SOURCE Oppenheimer & Co. Inc.